The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Stromal Antigen Targeting by a Humanised Monoclonal Antibody: An Early Phase II Trial of Sibrotuzumab in Patients with Metastatic Colorectal Cancer
Abstract
BACKGROUND: A novel immunological approach to colon cancer therapy is the antibody targeting of the fibroblast activation protein (FAP), which is highly expressed by stroma cells of this tumour. Unconjugated sibrotuzumab (BIBH 1), which is a humanised version of the murine anti-FAP mAb F19, was investigated for its anti-tumour activity, safety and pharmacokinetics. PATIENTS AND METHODS: Patients with metastatic colorectal cancer received weekly intravenous infusions of unconjugated sibrotuzumab at a dose of 100 mg over 12 scheduled weeks. The study was implemented as an open-label, uncontrolled, multicentre trial. RESULTS: 25 patients were enrolled. Patients had one or more measurable lesions, predominantly liver lesions, at baseline. At least 8 repeated weekly infusions of sibrotuzumab in 17 evaluable patients did not result in complete or partial remission. Rather, ongoing tumour progression was noted in all patients except for 2 patients with stable disease. However, progressive disease was also observed post-study in these 2 patients who received 1 and 6 additional infusions, respectively, of sibrotuzumab. Sibrotuzumab exhibited 2-compartment pharmacokinetics with a dominant terminal phase and t1/2 beta = 5.3 +/- 2.3 days. Adverse drug reactions (rigors/chills, nausea, flushing and one incidence of bronchospasm) were observed in 5 patients. Of the 24 patients given 2 or more infusions of sibrotuzumab, antibodies against sibrotuzumab were found in 3 patients (12.5%) after 4-12 infusions. CONCLUSIONS: Sibrotuzumab was well tolerated and safe. The minimal requirement for the continuation of this exploratory trial, of at least one complete or partial remission, or equivalently, of 4 patients with stable disease, was not met.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,562
Garin-Chesa, P., Old, L. J., & Rettig, W. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.18.7235 · Cited by 748
Radioimmunotherapy of B-Cell Lymphoma with [131I]Anti-B1 (Anti-CD20) Antibody
Kaminski, M. S., Zasadny, K. R., Francis, I. R., Milik, A. W., Ross, C. W., Moon, S. D., Crawford, S. M., Burgess, J. M., Petry, N. A., Butchko, G. M., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199308123290703 · Cited by 547
Scott, A. M., Wiseman, G., Welt, S., Adjei, A. A., Lee, F.-T., Hopkins, W., Divgi, C. R., Hanson, L. J., Mitchell, P., Gansen, D. N., et al. (2003) · PubMed · Cited by 438
Self-citationWelt, S., Divgi, C. R., Scott, A. M., Garin-Chesa, P., Finn, R. D., Graham, M., Carswell, E. A., Cohen, A., Larson, S. M., & Old, L. J. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.6.1193 · Cited by 266
Waldmann, T., Goldman, C., Bongiovanni, K., Sharrow, S., Davey, M., Cease, K., Greenberg, S., & Longo, D. (1988) · Blood · doi:10.1182/blood.v72.5.1805.1805 · Cited by 169
Monoclonal antibody therapy for solid tumors
Green, M. C., Murray, J. L., & Hortobágyi, G. N. (2000) · Cancer Treatment Reviews · doi:10.1053/ctrv.2000.0176 · Cited by 157
Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias.
Jurcic, J., Caron, P. C., Nikula, T. K., Papadopoulos, E., Finn, R. D., Gansow, O. A., Miller, W. H., Geerlings, M. W., Warrell, R. P., & Larson, S. M. (1995) · PubMed · Cited by 101
Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas.
Hellström, I., Beaumier, P. L., & Hellström, K. E. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.18.7059 · Cited by 91
Niedermeyer, J., Scanlan, M. J., Garin‐Chesa, P., Daiber, C., Fiebig, H., Old, L. J., Rettig, W. J., & Schnapp, A. (1997) · International Journal of Cancer · Cited by 91
Mathew, S., Scanlan, M. J., Raj, B. K. M., Murty, V. V. V. S., Garin‐Chesa, P., Old, L. J., Rettig, W. J., & Chaganti, R. S. K. (1995) · Genomics · doi:10.1016/0888-7543(95)80157-h · Cited by 76
Reff, M. E., & Heard, C. (2001) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00132-9 · Cited by 61
Tanswell, P., Garin‐Chesa, P., Rettig, W. J., Welt, S., Divgi, C. R., Casper, E. S., Finn, R. D., Larson, S. M., Old, L. J., & Scott, A. M. (2001) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2001.01335.x · Cited by 49
Self-citationColorectal cancer as a model for immunotherapy.
Foon, K. A., Yannelli, J. R., & Bhattacharya‐Chatterjee, M. (1999) · PubMed · Cited by 39
Cited by
A framework for advancing our understanding of cancer-associated fibroblasts
Sahai, E., Astsaturov, I., Cukierman, E., DeNardo, D. G., Egeblad, M., Evans, R. M., Fearon, D., Greten, F. R., Hingorani, S. R., Hunter, T., et al. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0238-1 · Cited by 3,863
Tumor microenvironment as a therapeutic target in cancer
Xiao, Y., & Yu, D. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107753 · Cited by 1,957
Turning foes to friends: targeting cancer-associated fibroblasts
Chen, X., & Song, E. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0004-1 · Cited by 1,879
The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities
Ho, W. J., Jaffee, E. M., & Zheng, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0363-5 · Cited by 1,287
Targeting the tumour stroma to improve cancer therapy
Valkenburg, K. C., de Groot, A. E., & Pienta, K. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0007-1 · Cited by 1,084
Metadata
- Authors
- Hofheinz, R.-D., al-Batran, S.-E., Hartmann, F., Hartung, G., Jäger, D., Renner, C., Tanswell, P., Kunz, U., Amelsberg, A., Kuthan, H., & Stehle, G.
- Venue
- Oncology Research and Treatment
- Publisher
- S. Karger AG
- Published
- 2003
- Volume
- 26
- Issue
- 1
- Pages
- 44-48
- ISSN
- 2296-5262 (ISSN-L)
- 2296-5270
- OpenAlex
- W2085121865
- Cited by
- 374
- References
- 14
- FWCI
- 1.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.